Arm cuff may stop stroke from worsening
NCT ID NCT07237542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a safe, non-drug treatment called remote ischemic preconditioning (RIC) to see if it can stop early neurological decline in people who have had a mild stroke caused by a blocked small artery. The treatment involves briefly inflating a blood pressure cuff on the arm to restrict blood flow, which may protect the brain. The study will enroll 910 adults within 48 hours of their stroke and compare those who receive RIC plus standard care to those who receive a sham procedure plus standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 910 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 years or older; 2. Diagnosed with acute ischemic stroke; 3. Clinical symptoms consistent with perforating artery infarction (NIHSS score ≤5, with consciousness item 1a ≤1); 4. Time from onset to randomization within 48 hours; 5. Diffusion-weighted imaging (DWI) showing a single infarct in the perforating artery territory with a maximum diameter ≤30 mm, meeting at least one of the following: (1) Diameter ≤15 mm and involving two or more axial slices; (2) Maximum diameter ≥15 mm; (3) Connected to the ventral surface of the pons but not crossing the midline; 6) Stenosis of parent artery \<70%; 7) Signed informed consent obtained from the patient or their legally authorized representative. Exclusion Criteria: 1. Received intravenous thrombolysis or endovascular treatment prior to randomization; 2. Secondary stroke caused by brain tumor, traumatic brain injury, hematologic disorders, or other conditions; 3. History of intracranial hemorrhage; 4. Presence of RIC contraindications, such as severe upper limb soft tissue injury, fracture, subclavian artery stenosis, or peripheral vascular disease; 5. Uncontrolled severe hypertension (systolic blood pressure \[BP\] ≥180 mmHg or diastolic BP ≥110 mmHg); 6. Severe hepatic or renal dysfunction (Alanine Aminotransferase or Aspartate Aminotransferase \> 3 × upper limit of normal; creatine kinase \>3 × upper limit of normal; estimated Glomerular Filtration Rate \< 30 mL / min / 1.73 m²); 7. Patients with thrombocytopenic purpura, coagulation disorders, or active visceral bleeding; 8. Patients in the acute phase of fundus hemorrhage; 9. History of severe aphasia or psychiatric disorders affecting clinical assessment; 10. Life expectancy \<90 days; 11. Pregnancy; 12. Inability to comply with follow-up; 13. Participation in other clinical trials.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Jinling Hospital, Medical School of Nanjing University, Nanjing
RECRUITINGNanjing, Jiangsu, 210002, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to catch a hidden heart rhythm after stroke
- Blood test may reveal who recovers after a stroke
- Can a smart bracelet and app stop a second stroke?
- Pharmacist and coach team takes aim at blood pressure after stroke